ENTITY
Wuxi Biologics

Wuxi Biologics (2269 HK)

419
Analysis
Health CareChina
WuXi Biologics (Cayman) Inc. is a leading open-access R&D capability and technology platform company serving the pharmaceutical, biotechnology, and medical device industries, with operations in China, U.S., and Iceland. We provide a broad and integrated portfolio of laboratory and manufacturing services throughout the drug and medical device R&D process. Our services are designed to help our global partners in shortening the cycle and lowering the cost of drug and medical device R&D through cost-effective and efficient solutions.
more
Refresh
26 Jul 2022 11:44

Legend Biotech Follow-On - A Little Opportunistic. Last Deal Did Well, After a Large Correction

Legend Biotech Corp (LEGN US), a non-wholly owned subsidiary of Hong Kong-listed Genscript Biotech (1548 HK), is planning to raise up to US$250m in...

Logo
300 Views
Share
24 Jul 2022 09:11

China Healthcare Weekly (July22)-Jiangsu Province VBP, CStone's Potential Sale, Irrational Mr Market

Jiangsu Province released VBP results on medical consumables. CStone proposed a potential sale of the business.We analyzed the logic behind. Maybe...

Logo
355 Views
Share
17 Jul 2022 12:47

Hong Kong Connect Flows: Tencent, Geely, Meituan, Wuxi Biologics

We highlight southbound weekly Hong Kong inflows into Tencent, Geely, as well as outflows from Meituan, and Wuxi Biologics.

Logo
339 Views
Share
17 Jul 2022 11:04

HK Short Interest: Innovent Biologics, Yeahka, CR Beer, Great Wall Motor

We highlight week on week short interest changes in Innovent Biologics, Yeahka, CR Beer, Great Wall Motor based on the latest HK SFC short...

Logo
324 Views
Share
05 Jul 2022 16:15

Hong Kong Connect Flows Monthly (June): Li Auto, Kuaishou, HKEx, Xpeng

We highlight the 7th month of consecutive inflows from mainland to HK and individual stocks with top inflows: Li Auto, Kuaishou, HKEx, Xpeng.

Logo
360 Views
Share
x